ClinicalTrials.gg
CompletedNCT05059301Updated Feb 15, 2023Results posted

A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above

A Phase 3 interventional study of RSVPreF3 OA investigational vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 19 sites in 3 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-15.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
770
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.

Enrollment
11th of 17
770 · median 976
Started
2021
with 3 others
Phase 3
15 of 17
none open now
Registered
4th of 17
by date
Lead sponsor
15 of 17
GlaxoSmithKline

Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one is the 11th largest by enrollment, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 4th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About arexvy

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing arexvy in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

The purpose of this study is to assess the lot-to-lot consistency in terms of immunogenicity and evaluate the safety and reactogenicity of 3 lots of the RSVPreF3 OA investigational vaccine administered as a single dose in adults ≥ 60 years of age (YOA).

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus
  • Adults aged 60 years and above
  • Lot-to-lot consistency
  • Safety
  • Reactogenicity
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol. A male or female ≥ 60 YOA at the time of first study intervention administration.
  • Participants living in the general community or in an assisted living facility that provides minimal assistance, such that the participant is primarily responsible for self care and activities of daily living.
  • Written or witnessed obtained from the participant prior to performance of any study specific procedure.
  • Participants who are medically stable in the opinion of the investigator at the time of vaccination. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, can participate in this study if considered by the investigator as medically stable.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Any confirmed or suspected or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history, and physical examination (no laboratory testing required).
  • History of any reaction or likely to be exacerbated by any component of the study intervention(s).
  • Hypersensitivity to latex.
  • Serious or unstable chronic illness.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.
  • Recurrent or un controlled neurological disorders or seizures. Participants with medically controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.

Prior/Concomitant therapy

  • Use of any or non registered product (drug, vaccine or medical device) other than the study intervention(s) during the period beginning 30 days before study intervention administration and ending 30 days after study intervention administration, or planned use during the study period.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after the study intervention administration, with the exception of inactivated and subunit influenza vaccines which can be administered up to 14 days before or from 14 days after the study vaccination.
  • Note: In case an emergency mass vaccination for an unforeseen public health threat (e.g. a pandemic) is recommended and/or organized by the public health authorities, outside the routine immunization program, the time period described above can be reduced if necessary for that vaccine provided it is used according to the local governmental recommendations and that the Sponsor is notified accordingly. Previous vaccination with an RSV vaccine.
  • Administration of long acting immune modifying drugs or planned administration at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the administration of the study intervention or planned administration during the study period.
  • Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune modifying drugs during the period starting 90 days prior to the study intervention administration or planned administration during the study period. For , this will mean prednisone ≥ 20 mg/day or equivalent. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non investigational vaccine/product (drug or invasive medical device).

Other exclusions

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Planned move during the study period that will prohibit participating in the study until study end.
  • Bedridden participants.
  • Participation of any study personnel or their immediate dependents, family, or household members.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
770 participants (actual)

Study arms

  • Experimental
    RSV OA_Lot 1

    Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 1 and AS01E adjuvant Lot A at Day 1 and were followed up until the study end (Month 6).

    Biological: RSVPreF3 OA investigational vaccine

  • Experimental
    RSV OA_Lot 2

    Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 2 and AS01E adjuvant Lot B at Day 1 and were followed up until the study end (Month 6).

    Biological: RSVPreF3 OA investigational vaccine

  • Experimental
    RSV OA_Lot 3

    Participants received 1 dose of a combination of the RSVPreF3 antigen Lot 3 and AS01E adjuvant Lot C at Day 1 and were followed up until the study end (Month 6).

    Biological: RSVPreF3 OA investigational vaccine

Interventions

  • One dose of a unique combination of the RSVPreF3 antigen lots (Lot 1, Lot 2 or Lot 3) and extemporaneously reconstituted with AS01E adjuvant lots (Lot A, Lot B and Lot C), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1.

06

What researchers measure

Primary outcomes

  1. RSVPreF3 Specific Immunoglobin (Ig)G Antibody Concentrations Expressed as Group Geometric Mean Concentration (GMC)

    Enzyme-linked immunosorbent assay (ELISA) was used to assess the concentrations of IgG antibodies against RSV PreF3 in serum samples.

    Time frame: At 30 days post-vaccination (Day 31)

Secondary outcomes

  1. RSVPreF3 Specific IgG Antibody Concentrations Expressed as Mean Geometric Increase (MGI)

    MGI was defined as the geometric mean of the within participant ratios of the post-vaccination RSV PreF3 IgG concentration over the pre-vaccination RSV PreF3 IgG concentration.

    Time frame: At 30 days post-vaccination (Day 31)

  2. Percentage of Participants Reporting Solicited Administration Site Events

    Solicited administration site adverse events (AEs) assessed were erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade.

    Time frame: Within 4 days (the day of vaccination and 3 subsequent days) after study intervention administration

  3. Percentage of Participants Reporting Solicited Systemic Events

    Solicited systemic events assessed were arthralgia, fatigue, fever \[defined as temperature equal to or above (\>=) 38 degrees Celsius (°C)/100.4 degrees Fahrenheit (°F)}, headache and myalgia. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination.

    Time frame: Within 4 days (the day of vaccination and 3 subsequent days) after study intervention administration

  4. Percentage of Participants Reporting at Least One Unsolicited Adverse Event

    An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited AE. Unsolicited AEs include serious, non-serious AEs and potential immune-mediated diseases (pIMDs).

    Time frame: Within 30 days (the day of vaccination and 29 subsequent days) after study intervention administration

  5. Percentage of Participants Reporting at Least One Serious Adverse Event (SAE)

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination.

    Time frame: From Day 1 up to study end (6 months after vaccination)

  6. Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMD)

    pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

    Time frame: From Day 1 up to study end (6 months after vaccination)

07

Results

Posted Feb 15, 2023

Participant flow

Participant flow — Overall Study
MilestoneRSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3
Started251253253
Completed249248248
Not completed255
Withdrew: Adverse event022
Withdrew: Lost to follow-up233

Outcome measures

PrimaryRSVPreF3 Specific Immunoglobin (Ig)G Antibody Concentrations Expressed as Group Geometric Mean Concentration (GMC)

Enzyme-linked immunosorbent assay (ELISA) was used to assess the concentrations of IgG antibodies against RSV PreF3 in serum samples.

Time frame:
At 30 days post-vaccination (Day 31)
Reported as:
Geometric mean · ELISA Units/milliliter
RSVPreF3 Specific Immunoglobin (Ig)G Antibody Concentrations Expressed as Group Geometric Mean Concentration (GMC)
ELISA Units/milliliterRSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3
RSVPreF3 Specific Immunoglobin (Ig)G Antibody Concentrations Expressed as Group Geometric Mean Concentration (GMC)86039.9 (78541.5 to 94254.3)80518 (73150 to 88628.2)94260.9 (86042.2 to 103264.7)
Statistical analysis
  • RSV OA_Lot 1 vs RSV OA_Lot 2 · Adjusted group gmc ratio: 1.06 · 95% CI 0.94 to 1.21
  • RSV OA_Lot 1 vs RSV OA_Lot 3 · Adjusted group gmc ratio: 0.92 · 95% CI 0.81 to 1.04
  • RSV OA_Lot 2 vs RSV OA_Lot 3 · Adjusted group gmc ratio: 0.87 · 95% CI 0.77 to 0.99
SecondaryRSVPreF3 Specific IgG Antibody Concentrations Expressed as Mean Geometric Increase (MGI)

MGI was defined as the geometric mean of the within participant ratios of the post-vaccination RSV PreF3 IgG concentration over the pre-vaccination RSV PreF3 IgG concentration.

Time frame:
At 30 days post-vaccination (Day 31)
Reported as:
Geometric mean · Ratio
RSVPreF3 Specific IgG Antibody Concentrations Expressed as Mean Geometric Increase (MGI)
RatioRSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3
RSVPreF3 Specific IgG Antibody Concentrations Expressed as Mean Geometric Increase (MGI)11.84 (10.53 to 13.31)11.29 (10.12 to 12.6)12.46 (11.13 to 13.94)
SecondaryPercentage of Participants Reporting Solicited Administration Site Events

Solicited administration site adverse events (AEs) assessed were erythema, pain and swelling. Any = occurrence of the adverse event regardless of intensity grade.

Time frame:
Within 4 days (the day of vaccination and 3 subsequent days) after study intervention administration
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Solicited Administration Site Events
Percentage of participantsRSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3
Erythema12.4 (8.6 to 17.2)11.6 (7.9 to 16.2)13.5 (9.5 to 18.3)
Pain58.2 (51.8 to 64.4)65.7 (59.5 to 71.6)62.7 (56.4 to 68.7)
Swelling6.8 (4 to 10.7)7.6 (4.6 to 11.6)7.9 (4.9 to 12)
SecondaryPercentage of Participants Reporting Solicited Systemic Events

Solicited systemic events assessed were arthralgia, fatigue, fever \[defined as temperature equal to or above (\>=) 38 degrees Celsius (°C)/100.4 degrees Fahrenheit (°F)}, headache and myalgia. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination.

Time frame:
Within 4 days (the day of vaccination and 3 subsequent days) after study intervention administration
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Solicited Systemic Events
Percentage of participantsRSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3
Arthralgia13.3 (9.3 to 18.1)13.9 (9.9 to 18.9)14.7 (10.6 to 19.7)
Fatigue28.1 (22.6 to 34.1)25.9 (20.6 to 31.8)27.8 (22.3 to 33.7)
Fever2 (0.7 to 4.6)1.6 (0.4 to 4)2.8 (1.1 to 5.6)
Headache25.7 (20.4 to 31.6)23.5 (18.4 to 29.2)22.2 (17.2 to 27.9)
Myalgia31.3 (25.6 to 37.5)34.3 (28.4 to 40.5)33.7 (27.9 to 39.9)
SecondaryPercentage of Participants Reporting at Least One Unsolicited Adverse Event

An unsolicited AE is any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited AE. Unsolicited AEs include serious, non-serious AEs and potential immune-mediated diseases (pIMDs).

Time frame:
Within 30 days (the day of vaccination and 29 subsequent days) after study intervention administration
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least One Unsolicited Adverse Event
Percentage of participantsRSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3
Percentage of Participants Reporting at Least One Unsolicited Adverse Event14.7 (10.6 to 19.7)14.6 (10.5 to 19.6)13.4 (9.5 to 18.3)
SecondaryPercentage of Participants Reporting at Least One Serious Adverse Event (SAE)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination.

Time frame:
From Day 1 up to study end (6 months after vaccination)
Reported as:
Number · Percentage of Participants
Percentage of Participants Reporting at Least One Serious Adverse Event (SAE)
Percentage of ParticipantsRSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3
Percentage of Participants Reporting at Least One Serious Adverse Event (SAE)3.2 (1.4 to 6.2)2.4 (0.9 to 5.1)2.8 (1.1 to 5.6)
SecondaryPercentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMD)

pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

Time frame:
From Day 1 up to study end (6 months after vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMD)
Percentage of participantsRSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3
Percentage of Participants Reporting at Least One Potential Immune-mediated Disease (pIMD)0.8 (0.1 to 2.8)0.4 (0 to 2.2)1.2 (0.2 to 3.4)

Adverse events

Collected over Solicited AEs were collected during the 4-day follow-up period after vaccination. Unsolicited AEs were collected during the 30-day follow-up period after vaccination. SAEs and pIMDs were collected throughout the study period (from Day 1 to Study end (6 months after vaccination)).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RSV OA_Lot 10/251 (0%)8/251 (3.2%)181/251 (72.1%)
RSV OA_Lot 22/253 (0.8%)6/253 (2.4%)192/253 (75.9%)
RSV OA_Lot 32/253 (0.8%)7/253 (2.8%)195/253 (77.1%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventRSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/2510/2532/253
Atrial fibrillationCardiac disorders1/2510/2531/253
Metastases to liverNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2510/2530/253
Metastases to lymph nodesNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2510/2530/253
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2510/2530/253
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2510/2530/253
COVID-19Infections and infestations1/2510/2530/253
SepsisInfections and infestations1/2510/2530/253
Ischaemic strokeNervous system disorders1/2510/2530/253
CholecystitisHepatobiliary disorders1/2510/2530/253
Most frequent other events
Showing 10 of 91
Most frequent other events
EventRSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3
Injection site painGeneral disorders145/251165/253159/253
MyalgiaMusculoskeletal and connective tissue disorders78/25187/25386/253
FatigueGeneral disorders70/25166/25372/253
HeadacheNervous system disorders65/25162/25357/253
ArthralgiaMusculoskeletal and connective tissue disorders34/25136/25339/253
Injection site erythemaGeneral disorders32/25129/25337/253
Injection site swellingGeneral disorders17/25120/25320/253
PyrexiaGeneral disorders8/2519/2539/253
NasopharyngitisInfections and infestations3/2512/2531/253
Urinary tract infectionInfections and infestations3/2510/2530/253

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3Total
Mean69.7 ± 6.670.1 ± 6.669.9 ± 6.669.9 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)RSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3Total
Female131131109371
Male120122144386
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RSV OA_Lot 1RSV OA_Lot 2RSV OA_Lot 3Total
ASIAN6101026
BLACK OR AFRICAN AMERICAN63413
NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER0101
OTHER88622
WHITE231231233695
08

Study locations

19 sites
  • GSK Investigational Site
    Waterbury, Connecticut 06708, United States
  • GSK Investigational Site
    Brooksville, Florida 34613, United States
  • GSK Investigational Site
    Immokalee, Florida 34142, United States
  • GSK Investigational Site
    Buford, Georgia 30519, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55402, United States
  • GSK Investigational Site
    Petal, Mississippi 39465, United States
  • GSK Investigational Site
    Omaha, Nebraska 68144, United States
  • GSK Investigational Site
    Greensboro, North Carolina 27408, United States
  • GSK Investigational Site
    Houston, Texas 77058, United States
  • GSK Investigational Site
    Vancouver, British Columbia V5Z 1K3, Canada
  • GSK Investigational Site
    Moncton, New Brunswick E1G1A7, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Toronto, Ontario M3J 2C5, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1J 2G2, Canada
  • GSK Investigational Site
    St-Charles-Borromée, Quebec J6E 2B4, Canada
  • GSK Investigational Site
    Quebec, G1W 4R4, Canada
  • GSK Investigational Site
    Eskilstuna, SE-631 88, Sweden
  • GSK Investigational Site
    Karlskrona, SE-371 79, Sweden
  • GSK Investigational Site
    Uppsala, SE-752 37, Sweden
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Jan 2022, 3 months.

Results were first posted in Feb 2023, 1 year after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 3 months is below that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2021
First posted
Sep 28, 2021
StartActual
Oct 1, 2021
Primary completionActual
Jan 24, 2022
CompletionActual
Jun 30, 2022
Results first posted
Feb 15, 2023
Last update
Feb 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05059301
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 28, 2021
Start date
Oct 1, 2021
Primary completion
Jan 24, 2022
Completion
Jun 30, 2022
Results posted
Feb 15, 2023
Last update
Feb 15, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arexvy

Start the discussion